NEVVI Medicare utilization intelligence

← back

MENDELSOHN, LAWRENCEMD NPI 1295717189 Clinician

Hematology-Oncology · LITTLE ROCK, AR

Specialty Hematology-Oncology — from billed Medicare claims
Trained UNIVERSITY OF ARKANSAS COLLEGE OF MEDICINE — medical school, self-reported to CMS
In practice about 46 years since medical school (class of 1980, self-reported to CMS)
Location LITTLE ROCK, AR · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 113 codes billed · 237,339 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-03

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9299 Injection, nivolumab, 1 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J9267 Injection, paclitaxel, 1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
J0185 Injection, aprepitant, 1 mg
J9025 Injection, azacitidine, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J1453 Injection, fosaprepitant, 1 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
J0461 Injection, atropine sulfate, 0.01 mg
80053 Blood test, comprehensive group of blood chemicals
J1626 Injection, granisetron hydrochloride, 100 mcg
J1434 Injection, fosaprepitant (focinvez), 1 mg
83615 Lactate dehydrogenase (enzyme) level
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
84550 Uric acid level, blood
J0894 Injection, decitabine, 1 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9041 Injection, bortezomib, 0.1 mg
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
82728 Ferritin (blood protein) level
82378 Carcinoembryonic antigen (cea) protein level
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96375 Injection of additional new drug or substance into vein
J2469 Injection, palonosetron hcl, 25 mcg
82784 Gammaglobulin (immune system protein) measurement
J1750 Injection, iron dextran, 50 mg
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96372 Injection of drug or substance under skin or into muscle
J0640 Injection, leucovorin calcium, per 50 mg
96413 Administration of chemotherapy into vein, 1 hour or less
88185 Flow cytometry technique for dna or cell analysis, each additional marker
J9190 Injection, fluorouracil, 500 mg
J9045 Injection, carboplatin, 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J9206 Injection, irinotecan, 20 mg
J3475 Injection, magnesium sulfate, per 500 mg
J3480 Injection, potassium chloride, per 2 meq
J1200 Injection, diphenhydramine hcl, up to 50 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
82607 Cyanocobalamin (vitamin b-12) level
J3490 Unclassified drugs
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
84153 Psa (prostate specific antigen) measurement, total
96415 Administration of chemotherapy into vein, each additional hour
82306 Vitamin d-3 level
82746 Folic acid level, serum
96417 Administration of additional new drug or substance into vein, 1 hour or less
83735 Magnesium level
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
83883 Nephelometry, test method using light
J7030 Infusion, normal saline solution , 1000 cc
J9060 Injection, cisplatin, powder or solution, 10 mg
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96361 Infusion into a vein for hydration, each additional hour
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96411 Administration of additional new drug or substance into vein using push technique
85610 Blood test, clotting time
J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms
81003 Automated urinalysis test
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
82668 Erythropoietin (protein) level
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
84443 Blood test, thyroid stimulating hormone (tsh)
86431 Rheumatoid factor level
96360 Infusion into a vein for hydration, 31-60 minutes
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
84165 Protein measurement, serum
86334 Immunologic analysis technique on serum (immunofixation)
99195 Drawing of blood for a medical problem
86304 Immunologic analysis for detection of tumor antigen, quantitative; ca 125
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J3489 Injection, zoledronic acid, 1 mg
86301 Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
83540 Iron level
83550 Iron binding capacity
84436 Thyroxine (thyroid chemical), total
83010 Haptoglobin (serum protein) level
85046 Red blood count automated, with additional calculations
96523 Irrigation of implanted venous access drug delivery device
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
82105 Alpha-fetoprotein (afp) level, serum
82565 Blood creatinine level
88184 Flow cytometry technique for dna or cell analysis, first marker
J2150 Injection, mannitol, 25% in 50 ml
96374 Injection of drug or substance into vein
51798 Ultrasound measurement of bladder capacity after voiding
J1940 Injection, furosemide, up to 20 mg
96377 Application of on-body injector for under skin injection
G0008 Administration of influenza virus vaccine
90661 Influenza vaccine, trivalent derived from cell cultures
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99239 Hospital discharge day management, more than 30 minutes
96409 Administration of chemotherapy into vein using push technique
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
85008 Microscopic examination for white blood cells
85730 Coagulation assessment blood test, plasma or whole blood

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.